12.05.24 -- October 2024 — CDMO Opportunities And Threats Report

In the last entry of our client checklist series, we delve into crucial aspects such as project management, decision-making, MSA negotiations, and building trust in CDMO-client partnerships.

AAV has become an increasingly popular vector for gene therapy applications, yet ongoing challenges related to process and analytical development often require significant expertise to navigate.

Though conducting your clinical trial in Australia may initially seem daunting, the benefits are ample. Australia is home to qualified CRO partners that will guide your CGT to regulatory success.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

Better understand the intricacies of AAV triple transfection and how advances in vector production and cell line optimization are enhancing gene therapy.

Whether you’re at the discovery stage or thinking about commercial production, gain useful insights on expression formats from transient transfection, through stable pools to stable clones.

A robust pharmaceutical quality system is pivotal in achieving safe and efficient drug manufacturing. Learn more about its importance and the optimal methods for implementation. 

Leveraging the right LVV manufacturing platform can accelerate timelines, better manage costs, and transform product development and potential for clinical success so that therapies reach patients in need.

Uncover how our collaborative approach positions us as an extended workbench for our partners, enabling faster, more effective solutions for patients.